https://www.facingourrisk.org/research-clinical-trials/study/196/denosumab-for-breast-cancer-risk-reduction-in-women-with-an-inherited-brca1-mutation-the-breast-cancer-prevention-study
Prevention
Prevention study enrolling women ages 25-55 with a BRCA1 mutation
This is a study to test the effectiveness of a drug (denosumab) on preventing the development of breast cancer in women with an inherited BRCA1 mutation.
Denosumab is a drug that is currently used to treat bone loss in order to reduce the risk of broken bones in healthy people, and is also used to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research has shown that denosumab may also reduce the risk of developing breast cancer in women with an inherited BRCA1 mutation.
https://www.facingourrisk.org/research-clinical-trials/study/101/a-study-to-compare-two-surgical-procedures-in-women-with-brca1-mutations-to-assess-reduced-risk-of-ovarian-cancer-sorock
Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries
SOROCk [NRG-CC008] is a clinical trial studying if removal of just the fallopian tubes can reduce the risk of ovarian cancer nearly as much as removing both the ovaries and fallopian tubes among women with an inherited BRCA1 mutation. The main benefit of removing only the fallopian tubes and not the ovaries is to prevent surgically-induced menopause. The study will also examine various patient-reported quality of life outcomes. Researchers believe that most ovarian cancers first begin in the fallopian tubes, suggesting that removing the fallopian tubes only may prevent the development of ovarian cancer. This concept has never been formally testing in a clinical trial.
https://www.facingourrisk.org/research-clinical-trials/study/291/patrol-study-prostate-cancer-screening-for-people-at-genetic-risk-for-aggressive-disease
Prevention
Screening study for people with a mutation linked to prostate cancer risk
The PATROL (Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease) study is for people at risk for prostate cancer because they carry one or more genes that are known or suspected to increase prostate cancer risk: BRCA2, HOXB13, ATM, BRCA1, MLH1, MSH2, MSH6, PALB2, PMS2, CHEK2, RAD51D, or TP53.
https://www.facingourrisk.org/research-clinical-trials/study/293/comparing-screening-methods-for-detection-of-early-stage-gastric-cancer-in-people-with-a-chd1-genetic-mutation
Prevention
Gastric cancer screening study for people with a CHD1 inherited mutation
This study will compare a new technique of screening for a type of inherited gastric cancer known as diffuse hereditary gastric cancer (DHGC) to see if it can identify cancer better than the current recommended screening.
https://www.facingourrisk.org/research-clinical-trials/study/72/men-at-high-genetic-risk-for-prostate-cancer
Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation
The National Institutes of Health has a clinical trial for men at high genetic risk for prostate cancer. This is trial is for men without prostate cancer, ages 30 to 75, who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or FANC (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, and FANCM). The trial involves screening MRI of the prostate every two years and biopsy of the prostate if the MRI is abnormal. There is no cost for travel or study-related tests.
https://www.facingourrisk.org/research-clinical-trials/study/278/cancer-prevention-vaccine-nous-209-for-people-with-lynch-syndrome
Prevention
Prevention study for people with Lynch syndrome
This study is testing a vaccine, known as the Nous-209 vaccine, which is intended to decrease the chances that people with Lynch syndrome will develop polyps that can turn into cancer.
https://www.facingourrisk.org/research-clinical-trials/study/288/testing-the-safety-and-action-of-the-investigational-drug-rec-4881-in-people-with-familial-adenomatous-polyposis-fap
Prevention
Prevention study for people with an APC mutation and FAP who have had colectomy surgery
This study is looking at how safe and effective the research drug REC-4881 is for treating polyps in people with Familial Adenomatous Polyposis (FAP). Participants will receive the oral drug REC-4881. A participant's dose will depend on when they join the study.
https://www.facingourrisk.org/research-clinical-trials/study/273/testing-a-combination-of-vaccines-for-cancer-prevention-in-lynch-syndrome
Prevention
Testing A Combination Of Vaccines For Cancer Prevention In Lynch Syndrome
This study is being done to assess the safety and effectiveness of a series of vaccines (Tri-Ad5), together with another drug (N-803) that magnifies the body’s response to vaccines, to see if there is an effect on the risk of developing colon and other cancers in LS patients.
https://www.facingourrisk.org/research-clinical-trials/study/284/testing-a-vaccine-for-treating-or-preventing-triple-negative-breast-cancer
Prevention
Prevention study for people with a BRCA1, BRCA2 or PALB2 inherited mutation who are planning to undergo risk-reducing mastectomy.
Researchers are studying the affects of this breast cancer vaccine on the immune system in two groups of people:
https://www.facingourrisk.org/research-clinical-trials/study/227/pancreatic-cancer-early-detection-for-people-at-high-risk
Prevention
Registry and biobank for high risk people undergoing pancreatic cancer screening
The study will collect clinical information, family history, and samples (blood, saliva or cheek swab) from people and families at risk for pancreatic cancer. Collecting this information and samples will create a resource to drive research necessary for early detection and prevention of pancreatic ductal adenocarcinoma (PDAC).
https://www.facingourrisk.org/research-clinical-trials/study/256/early-detection-of-colorectal-cancer-for-people-with-lynch-syndrome
Prevention
People with Lynch Syndrome at risk for colon cancer
This study will colect blood and stool samples to detect colorectal cancer or precancerous polyps in people with Lynch syndrome.
https://www.facingourrisk.org/research-clinical-trials/study/45/wisdom-study
Prevention
Study to Determine if Breast Cancer Screening can be Made Better by Personalizing Each Woman’s Mammogram Schedule
The goal of the Wisdom Study is to determine if breast cancer screening can be made better by personalizing each woman’s mammogram schedule, compared to the current one-size-fits-all, annual approach. The Wisdom Study is designed to end the confusion about when to start and how often to have a mammogram. For more information, visit the WISDOM Study website.
https://www.facingourrisk.org/research-clinical-trials/study/257/study-for-women-at-increased-risk-of-developing-breast-cancer
Prevention
This study will create a system to assess an individual’s risk of breast cancer
This study will create a system to assess an individual’s risk of breast cancer based on random sampling of normal breast tissue as well as determine new and help understand previously identified risk biomarkers.
https://www.facingourrisk.org/research-clinical-trials/study/260/screening-in-men-at-high-risk-of-developing-prostate-cancer
Prevention
Screening using MRI for men at risk of developing prostate cancer
This study will determine if prostate magnetic resonance imaging (MRI) will find prostate cancer in men at high risk of developing prostate cancer.
https://www.facingourrisk.org/research-clinical-trials/study/258/my-best-gi-eating-study
Prevention
Diet and weight loss study for people who are overweight and at increased risk of colorectal cancer
This study will test three different diets in people who are overweight and who have an increased risk of colorectal cancer. The study will look at whether these diets improve eating and possibly lead to weight loss.
https://www.facingourrisk.org/research-clinical-trials/study/205/risk-reducing-salpingectomy-with-delayed-oophorectomy-as-an-alternative-to-risk-reducing-salpingo-oophorectomy-in-high-risk-women
Prevention
Prevention study for women at high risk for ovarian cancer
This study is looking at whether removal of the fallopian tubes (salpingectomy) followed by removal of the ovaries (oophorectomy) at a later date closer to the time of natural menopause may reduce the risk of ovarian cancer nearly as much as removing both the ovaries and fallopian tubes at the same time (salpingo-oophorectomy) among women with an inherited BRCA1, BRCA2, BRIP1, RAD51C or RAD51D mutation. Removing the fallopian tubes only first and the ovaries at a later time closer to natural menopause may lessen menopausal symptoms while still lowering the risk for ovarian cancer.
https://www.facingourrisk.org/research-clinical-trials/study/289/testing-the-drug-obeticholic-acid-for-familial-adenomatous-polyposis
Prevention
Prevention study for people with an APC mutation and FAP or AFAP who have polyps in remaining tissue after colectomy surgery
This study is looking at whether obeticholic acid (OCA) is safe and has a beneficial effect on the number of polyps in the small bowel and colon in people with familial adenomatous polyposis (FAP). OCA is a drug similar to a bile acid the body's liver makes. Researchers believe OCA may help keeping cancer from developing. OCA is already FDA approved to treat a type of liver disease. There have been studies showing that OCA decreases inflammation and fibrosis. However, it is not yet known whether OCA works on reducing the number of polyps in patients with FAP.
https://www.facingourrisk.org/research-clinical-trials/study/172/testing-a-vaccine-for-cancer-prevention-in-people-with-a-brca1-or-brca2-mutation
Prevention
People with a BRCA1 or BRCA2 mutation
This study will look at a new vaccine known as INO-5401 used alone or combined with a second vaccine called INO-9012. The study will test if the vaccine is safe (without large side effects) and test a new way of giving vaccines. It will also test whether the vaccine activates the immune system. A goal of this research is to reduce cancer risk in people with a BRCA1 or BRCA2 mutation. Additional studies will be needed to learn if this vaccine approach lowers cancer risk in mutation carriers.
https://www.facingourrisk.org/research-clinical-trials/study/281/studying-the-use-of-naproxen-and-aspirin-for-cancer-prevention-in-people-with-lynch-syndrome
Prevention
Prevention study for people with Lynch syndrome
The trial is enrolling people with Lynch syndrome. On average, the length of this study will last one year from the start of enrollment to completion. The study will measure the effect of naproxen or aspirin on the immune cells in the gastrointestinal tract of people with Lynch syndrome. The trial will also evaluate any symptoms from the medications and any other changes of the colon and rectum.
https://www.facingourrisk.org/research-clinical-trials/study/222/pancreatic-cancer-screening-studycaps5
Prevention
Screening study for people at high risk for pancreatic cancer
CAPS5 is a study looking at screening for early cancer in people with an elevated lifetime risk of developing pancreatic cancer. The goal is to study biomarkers derived from images and tissue samples (blood, pancreas fluid, duodenal fluid) for the early detection of pancreatic cancer and precancerous lesions.
https://www.facingourrisk.org/research-clinical-trials/study/217/restoring-sensation-after-diep-flap-reconstruction
Prevention
Study for people undergoing DIEP flap reconstruction
The goal of this study is to look at how well a nerve graft works for improving sensation to the reconstructed breast after mastectomy in people undergoing DIEP flap reconstruction (deep inferior epigastric perforator flap).
https://www.facingourrisk.org/research-clinical-trials/study/180/prostate-cancer-genetic-risk-evaluation-and-screening-study-progress
Prevention
People at high risk for prostate cancer due to an inherited mutation
This study will look at how enhanced prostate cancer screening using MRI will improve early detection rates and further understanding of how inherited mutations can lead to development of prostate cancer.
https://www.facingourrisk.org/research-clinical-trials/study/141/blood-markers-of-early-pancreas-cancer
Prevention
Observational study for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk.
The purpose of this study is to try to find markers of early pancreatic cancer for individuals at higher-than-average risk, expedite the diagnosis in individuals with symptoms, and substantially improve an individual's chance of surviving the disease.
https://www.facingourrisk.org/research-clinical-trials/study/229/exploring-the-psychosocial-implications-of-individuals-with-a-genetic-test-result-that-was-later-reclassified
Prevention
Interview for people who's genetic test results were reclassified
Researchers at Bay Path University are conducting virtual/phone interviews with individuals who have received a reclassified genetic test result to cancer related genes. This study will help researchers learn the psychosocial implications and experiences of those who have received a reclassified genetic test result when undergoing hereditary cancer gene testing, (for example, your original genetic test results showed a variant of uncertain significance that was later found to be harmful or harmless).
https://www.facingourrisk.org/research-clinical-trials/study/250/helping-latinas-understand-their-risk-for-breast-cancer-and-get-breast-cancer-care
Prevention
Latinas with a high risk of breast cancer
This study will teach Latinas with a high risk of breast cancer about how diet, exercise, ethnicity, genetics and screening and prevention guidelines may impact their likelihood for developing breast cancer.
https://www.facingourrisk.org/research-clinical-trials/study/259/upright-mri-for-prostate-cancer-screening
Prevention
Screening for prostate cancer using upright MRI
This study will compare the effectiveness of an upright magnetic resonance imaging (MRI) compared to prostate specific antigen (PSA) and current MRI imaging for prostate cancer screening.
https://www.facingourrisk.org/research-clinical-trials/study/266/helping-people-with-a-genetic-mutation-in-brca1-brca2-or-lynch-syndrome-talk-to-their-family-members-about-their-risk-for-cancer-and-find-the-best-way-to-get-family-members-tested
Prevention
People with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome who have relatives who have not been tested
The IGNITE-TX study is all about helping people with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome talk to their family members about their risk for cancer and find the best way to get family members tested.
https://www.facingourrisk.org/research-clinical-trials/study/137/developing-a-test-for-the-detection-of-ovarian-cancer
Prevention
The purpose of this study is to develop a test for early detection of ovarian cancer. Two patient populations are included in this study: women scheduled for surgery or testing for suspected but undiagnosed ovarian/fallopian tube cancer, and women with a BRCA1 or BRCA2 mutation who are scheduled for a risk-reducing salpingo-oophorectomy. The study will examine DNA from a washing of the uterus (womb) and proteins found in the blood to see if they can detect ovarian cancer.
https://www.facingourrisk.org/research-clinical-trials/study/121/screening-for-pancreatic-cancer-in-patients-with-an-inherited-brca1-brca2-palb2-or-atm-mutation
Prevention
Improved screening for pancreatic cancer in high-risk groups, such as people with an inherited BRCA1, BRCA2, ATM, or PALB2 mutation, may help find cancer early and improve survival rates. People enrolled in this study will undergo screening using endoscopic ultrasound or MRI of the abdomen.
https://www.facingourrisk.org/research-clinical-trials/study/138/validating-a-blood-test-for-early-ovarian-cancer-detection-in-high-risk-women-and-families
Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation
The goal of MiDe is to develop a clinical diagnostic test to detect early onset ovarian cancer, as currently, there are no good screening or early detection tests available. Participants can be expected to provide up to 4 tubes of blood every 6 months for up to 5 years. We can collect these samples through mobile phlebotomy all around the US.
https://www.facingourrisk.org/research-clinical-trials/study/109/blood-tests-to-measure-ovarian-reserves-in-women-with-a-brca-mutation-or-women-treated-for-early-stage-breast-cancer
Prevention
The purpose of this study is to see how cancer treatment affects the ovaries, such as the impact on conceiving a child or the early onset of menopause. Comparatively, the study will also look at high-risk women with BRCA1/2 mutations (and no evidence of breast or ovarian cancer).
The study will check blood levels of hormones that the ovaries produce and will use questionnaires to gather information about participant menstrual cycles, health, and pregnancies.
https://www.facingourrisk.org/research-clinical-trials/study/95/pancreatic-cancer-screening-study-for-high-risk-people
Prevention
The purpose of this study is to screen and detect pancreatic cancer and precancer in people with either a strong family history of pancreatic cancer, or an inherited mutation associated with pancreatic cancer risk.
Magnetic Resonance Imaging (MRI) will be used to screen for early stage pancreatic cancer. Participants will also be asked to donate a blood sample at specific intervals for the creation of a blood bank necessary for the development of a blood-based screening test for pancreatic cancer.
https://www.facingourrisk.org/research-clinical-trials/study/93/denosumab-and-mammographic-density-in-premenopausal-women-with-dense-breasts-trident
Prevention
The purpose of this study is to evaluate if denosumab can reduce the breast density of premenopausal women who have dense breasts. Denosumab is an FDA-approved injectable medication that is used to treat osteoporosis and to prevent fractures in cancer patients with bone metastases. This study could help us identify novel ways to prevent breast cancer in younger women.
https://www.facingourrisk.org/research-clinical-trials/study/89/study-for-people-with-unexpected-genetic-results
Prevention
A new study is recruiting people who received unexpected genetic test results about their cancer risk after having genetic testing done for some other reason.
This is a study of people with "secondary results” from genetic testing. Secondary results are unexpected. They are not related to the reason the person had the genetic test but are shared because they may be very important to the person’s health. Most secondary results have to do with high risks for health problems that can be treated or prevented. Many of these results are related to cancer risk. If you think you have received a secondary result, you may be eligible to join this study.
https://www.facingourrisk.org/research-clinical-trials/study/20/pancreatic-cancer-early-detection
Prevention
This is a study looking at esophageal ultrasound and Magnetic Resonance Imaging (MRI) as a screening for pancreatic cancer in high risk individuals.
Additional Results on Clinicaltrials.gov Prevention, Detection & Risk
114 results
Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer
NCT ID: NCT04473833 (https://classic.clinicaltrials.gov/show/NCT04473833)
MIRAI-MRI: Comparing Screening MRI for Patients at High Risk for Breast Cancer Identified by Mirai and Tyrer-Cuzick
NCT ID: NCT05968157 (https://classic.clinicaltrials.gov/show/NCT05968157)
Stool DNA to Improve Colorectal Cancer Screening Among Alaska Native People
NCT ID: NCT04336397 (https://classic.clinicaltrials.gov/show/NCT04336397)
Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia
NCT ID: NCT04427527 (https://classic.clinicaltrials.gov/show/NCT04427527)
A Smartphone-Based Intervention to Improve Colorectal Cancer Screening in African American Men
NCT ID: NCT06052202 (https://classic.clinicaltrials.gov/show/NCT06052202)
MRI Screening in Men at High Risk of Developing Prostate Cancer
NCT ID: NCT05608694 (https://classic.clinicaltrials.gov/show/NCT05608694)
Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort
NCT ID: NCT05384535 (https://classic.clinicaltrials.gov/show/NCT05384535)
Virtual Human Delivered Nutrition Module for Colorectal Cancer Prevention
NCT ID: NCT04192071 (https://classic.clinicaltrials.gov/show/NCT04192071)
Shared Decision-making and Colorectal Cancer Screening
NCT ID: NCT04748380 (https://classic.clinicaltrials.gov/show/NCT04748380)
Promoting Informed Choice for Breast Cancer Screening: A Longitudinal Study
NCT ID: NCT05838417 (https://classic.clinicaltrials.gov/show/NCT05838417)
Impact of Protect Your Colon™ on CRC Screening
NCT ID: NCT05929820 (https://classic.clinicaltrials.gov/show/NCT05929820)
A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals
NCT ID: NCT03250078 (https://classic.clinicaltrials.gov/show/NCT03250078)
Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk
NCT ID: NCT02478892 (https://classic.clinicaltrials.gov/show/NCT02478892)
Engaging Black Men in Colorectal Cancer Screening
NCT ID: NCT05980182 (https://classic.clinicaltrials.gov/show/NCT05980182)
Developing and Evaluating Culturally Relevant Interventions to Improve Breast Cancer Screening
NCT ID: NCT05665660 (https://classic.clinicaltrials.gov/show/NCT05665660)
MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma
NCT ID: NCT03699995 (https://classic.clinicaltrials.gov/show/NCT03699995)
A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus
NCT ID: NCT03937453 (https://classic.clinicaltrials.gov/show/NCT03937453)
Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics
NCT ID: NCT05694559 (https://classic.clinicaltrials.gov/show/NCT05694559)
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
NCT ID: NCT05625659 (https://classic.clinicaltrials.gov/show/NCT05625659)
Aim 3, Optimizing CRC Screening in Patients With Diabetes in Safety-net Primary Care Settings
NCT ID: NCT05785780 (https://classic.clinicaltrials.gov/show/NCT05785780)
Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women
NCT ID: NCT05298605 (https://classic.clinicaltrials.gov/show/NCT05298605)
The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts
NCT ID: NCT05667532 (https://classic.clinicaltrials.gov/show/NCT05667532)
Prostate Cancer Genetic Risk Evaluation and Screening Study
NCT ID: NCT05129605 (https://classic.clinicaltrials.gov/show/NCT05129605)
Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC
NCT ID: NCT04890054 (https://classic.clinicaltrials.gov/show/NCT04890054)
Impact of Colorectal Cancer and Nutrition Education Program Among Minority Patients With Type 2 Diabetes
NCT ID: NCT05765214 (https://classic.clinicaltrials.gov/show/NCT05765214)
Upright MRI for Prostate Cancer Screening
NCT ID: NCT03474913 (https://classic.clinicaltrials.gov/show/NCT03474913)
A Patient-centered Intervention Using Technology to Reduce Colorectal Cancer Disparities in Primary Care
NCT ID: NCT03407417 (https://classic.clinicaltrials.gov/show/NCT03407417)
Early Detection of Breast Cancer
NCT ID: NCT06043661 (https://classic.clinicaltrials.gov/show/NCT06043661)
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
NCT ID: NCT04030507 (https://classic.clinicaltrials.gov/show/NCT04030507)
The PRIME-CRC Trial to Promote CRC Screening in Rural Communities
NCT ID: NCT04313114 (https://classic.clinicaltrials.gov/show/NCT04313114)
The Purpose of This Study is to Determine the Frequency of Colorectal Cancer in Male and Female Endurance Athletes Between the Ages of 35 and 50
NCT ID: NCT05419531 (https://classic.clinicaltrials.gov/show/NCT05419531)
Educate, Assess Risk and Overcoming Barriers to Colorectal Screening Among African Americans
NCT ID: NCT03640208 (https://classic.clinicaltrials.gov/show/NCT03640208)
Vaginal Fluid Collection for Detection of Endometrial Cancer
NCT ID: NCT06294886 (https://classic.clinicaltrials.gov/show/NCT06294886)
BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity
NCT ID: NCT05051631 (https://classic.clinicaltrials.gov/show/NCT05051631)
Addressing Disparities in Colorectal Cancer Screening in Black and Underserved Phoenix Communities
NCT ID: NCT05447923 (https://classic.clinicaltrials.gov/show/NCT05447923)
Cone Beam Breast CT for Breast Cancer Screening
NCT ID: NCT05036096 (https://classic.clinicaltrials.gov/show/NCT05036096)
Droplet-BC Screening Test for the Detection of Breast Cancer, the DROPLET-BC Study
NCT ID: NCT04671498 (https://classic.clinicaltrials.gov/show/NCT04671498)
Empowering Latinas to Obtain Guideline Concordant Screenings
NCT ID: NCT05841355 (https://classic.clinicaltrials.gov/show/NCT05841355)
Interventional Program Educates, Identifies + Overcomes Barriers to Complete Screening Mammography
NCT ID: NCT04348123 (https://classic.clinicaltrials.gov/show/NCT04348123)
Eliminating Barriers to Colorectal Cancer Screening Using Rapid Cycle Testing: A Pilot Study
NCT ID: NCT05524428 (https://classic.clinicaltrials.gov/show/NCT05524428)
Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening
NCT ID: NCT04904757 (https://classic.clinicaltrials.gov/show/NCT04904757)
A Study to Compare the Effectiveness of Two Types of Ultrasound Technologies in Women Who Have Had Breast Cancer
NCT ID: NCT05408260 (https://classic.clinicaltrials.gov/show/NCT05408260)
A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
NCT ID: NCT03729115 (https://classic.clinicaltrials.gov/show/NCT03729115)
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
NCT ID: NCT06122896 (https://classic.clinicaltrials.gov/show/NCT06122896)
Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts
NCT ID: NCT04854304 (https://classic.clinicaltrials.gov/show/NCT04854304)
Virtual Colonoscopy Using Omnipaque as a Contrast Agent
NCT ID: NCT04582500 (https://classic.clinicaltrials.gov/show/NCT04582500)
Exploring Cultural Acceptability of Community Breast Cancer Risk Assessment Among Hispanic Women in Maricopa County
NCT ID: NCT06112795 (https://classic.clinicaltrials.gov/show/NCT06112795)
Stool Sample Collection Study
NCT ID: NCT06294873 (https://classic.clinicaltrials.gov/show/NCT06294873)
Anamorelin Study for Advanced Pancreatic Cancer
NCT ID: NCT04844970 (https://classic.clinicaltrials.gov/show/NCT04844970)
Salud en Mis Manos - Breast and Cervical Cancer Prevention and Early Detection - Expansion 2
NCT ID: NCT06082882 (https://classic.clinicaltrials.gov/show/NCT06082882)
Searching for Masses and Calcifications at the Same Time in Breast Cancer Screening
NCT ID: NCT05975736 (https://classic.clinicaltrials.gov/show/NCT05975736)
Mammogram Mail- and Phone-based Interventions
NCT ID: NCT05853848 (https://classic.clinicaltrials.gov/show/NCT05853848)
Project 1: Self-Triage by 2D Full-field Digital Mammography or Synthetic Images
NCT ID: NCT05960188 (https://classic.clinicaltrials.gov/show/NCT05960188)
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
NCT ID: NCT05287451 (https://classic.clinicaltrials.gov/show/NCT05287451)
FHIR-Enhanced RealRisks to Improve Accuracy of Breast Cancer Risk Assessments
NCT ID: NCT05810025 (https://classic.clinicaltrials.gov/show/NCT05810025)
Biennial CEM in Women With a Personal History of Breast Cancer
NCT ID: NCT06105749 (https://classic.clinicaltrials.gov/show/NCT06105749)
Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care
NCT ID: NCT05483283 (https://classic.clinicaltrials.gov/show/NCT05483283)
Autoantibodies in Breast Cancer Detection
NCT ID: NCT03623945 (https://classic.clinicaltrials.gov/show/NCT03623945)
A Sociolinguistic-enabled Web Application to Develop Precision Health Intervention for African Americans
NCT ID: NCT04705363 (https://classic.clinicaltrials.gov/show/NCT04705363)
Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome
NCT ID: NCT04009148 (https://classic.clinicaltrials.gov/show/NCT04009148)
Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy
NCT ID: NCT05678322 (https://classic.clinicaltrials.gov/show/NCT05678322)
Reducing Metabolic Dysregulation in Dyads
NCT ID: NCT06117241 (https://classic.clinicaltrials.gov/show/NCT06117241)
A Cross-sectional Partnership to Improve Prevention
NCT ID: NCT05903885 (https://classic.clinicaltrials.gov/show/NCT05903885)
Colorectal Cancer Screening in Cystic Fibrosis
NCT ID: NCT05362344 (https://classic.clinicaltrials.gov/show/NCT05362344)
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
NCT ID: NCT05373823 (https://classic.clinicaltrials.gov/show/NCT05373823)
A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation
NCT ID: NCT06059963 (https://classic.clinicaltrials.gov/show/NCT06059963)
African Cancer Genome: GMD
NCT ID: NCT05754658 (https://classic.clinicaltrials.gov/show/NCT05754658)
Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors
NCT ID: NCT03971591 (https://classic.clinicaltrials.gov/show/NCT03971591)
Protocol for Women at Increased Risk of Developing Breast Cancer
NCT ID: NCT00291096 (https://classic.clinicaltrials.gov/show/NCT00291096)
My Best GI Eating Study
NCT ID: NCT05396846 (https://classic.clinicaltrials.gov/show/NCT05396846)
Magnetic Resonance Imaging of Breast Cancer
NCT ID: NCT01035112 (https://classic.clinicaltrials.gov/show/NCT01035112)
Blood Markers of Early Pancreas Cancer
NCT ID: NCT03568630 (https://classic.clinicaltrials.gov/show/NCT03568630)
Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients, CORAL Study
NCT ID: NCT05410977 (https://classic.clinicaltrials.gov/show/NCT05410977)
Nipple Aspirate Fluid in Detecting Breast Cancer
NCT ID: NCT03715959 (https://classic.clinicaltrials.gov/show/NCT03715959)
The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC) Pilot Feasibility Study
NCT ID: NCT06064149 (https://classic.clinicaltrials.gov/show/NCT06064149)
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
NCT ID: NCT06151223 (https://classic.clinicaltrials.gov/show/NCT06151223)
Comparison of Synthetic Mammography Versus Full-Field Digital Mammography in Image Interpretation and Performance Metrics
NCT ID: NCT05056818 (https://classic.clinicaltrials.gov/show/NCT05056818)
The Effect of IBD Flares on Serum PSA
NCT ID: NCT03558048 (https://classic.clinicaltrials.gov/show/NCT03558048)
The Genomic Medicine at VA Study
NCT ID: NCT04331535 (https://classic.clinicaltrials.gov/show/NCT04331535)
New Onset Diabetes Management for Earlier Detection of Pancreatic Cancer (NODMED)
NCT ID: NCT05188586 (https://classic.clinicaltrials.gov/show/NCT05188586)
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
NCT ID: NCT05471128 (https://classic.clinicaltrials.gov/show/NCT05471128)
Time-Restricted Eating and Mindfulness-Based Stress Reduction to Reduce the Risk of Early-Onset Colorectal Cancer
NCT ID: NCT06022887 (https://classic.clinicaltrials.gov/show/NCT06022887)
Pancreatic Cancer Early Detection Program
NCT ID: NCT02206360 (https://classic.clinicaltrials.gov/show/NCT02206360)
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
NCT ID: NCT04825834 (https://classic.clinicaltrials.gov/show/NCT04825834)
With Love, Grandma ("Con Cariño, Abuelita") Pilot Study
NCT ID: NCT05721976 (https://classic.clinicaltrials.gov/show/NCT05721976)
Developing a Test for the Detection of Ovarian Cancer
NCT ID: NCT04794322 (https://classic.clinicaltrials.gov/show/NCT04794322)
Early Detection of Breast Cancer in Women With Suspicious Mammograms
NCT ID: NCT03147430 (https://classic.clinicaltrials.gov/show/NCT03147430)
Real-time Computer-Aided Detection of Colonic Adenomas With NEC WISE VISION® Endoscopy
NCT ID: NCT05611151 (https://classic.clinicaltrials.gov/show/NCT05611151)
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
NCT ID: NCT00539162 (https://classic.clinicaltrials.gov/show/NCT00539162)
Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)
NCT ID: NCT05752448 (https://classic.clinicaltrials.gov/show/NCT05752448)
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
NCT ID: NCT04294927 (https://classic.clinicaltrials.gov/show/NCT04294927)
Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
NCT ID: NCT00843375 (https://classic.clinicaltrials.gov/show/NCT00843375)
Writing Interventions in Breast Cancer Patients Taking Aromatase Inhibitors
NCT ID: NCT04651452 (https://classic.clinicaltrials.gov/show/NCT04651452)
Predicting Chronic Pain Following Breast Surgery
NCT ID: NCT04967352 (https://classic.clinicaltrials.gov/show/NCT04967352)
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
NCT ID: NCT04722692 (https://classic.clinicaltrials.gov/show/NCT04722692)
Collection of Samples USOPTIVAL Study
NCT ID: NCT04792684 (https://classic.clinicaltrials.gov/show/NCT04792684)
A Study of Using Social Networks to Encourage Three Peers to Complete Screening for Colorectal Cancer
NCT ID: NCT05793593 (https://classic.clinicaltrials.gov/show/NCT05793593)
Pancreatic Cancer Detection Consortium
NCT ID: NCT06388967 (https://classic.clinicaltrials.gov/show/NCT06388967)
Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer
NCT ID: NCT05732623 (https://classic.clinicaltrials.gov/show/NCT05732623)
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
NCT ID: NCT04711109 (https://classic.clinicaltrials.gov/show/NCT04711109)
YES Study - Newly Diagnosed/Metastatic Intervention
NCT ID: NCT04379414 (https://classic.clinicaltrials.gov/show/NCT04379414)
Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases
NCT ID: NCT04973007 (https://classic.clinicaltrials.gov/show/NCT04973007)
A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer
NCT ID: NCT06312124 (https://classic.clinicaltrials.gov/show/NCT06312124)
Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.
NCT ID: NCT05113927 (https://classic.clinicaltrials.gov/show/NCT05113927)
Early Detection of Advanced Adenomas and Colorectal Cancer
NCT ID: NCT06342440 (https://classic.clinicaltrials.gov/show/NCT06342440)
RANKL Inhibition and Mammographic Breast Density
NCT ID: NCT04067726 (https://classic.clinicaltrials.gov/show/NCT04067726)
Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast
NCT ID: NCT03789162 (https://classic.clinicaltrials.gov/show/NCT03789162)
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT ID: NCT04961996 (https://classic.clinicaltrials.gov/show/NCT04961996)
The PROMISE Study: Duavee in Women With DCIS
NCT ID: NCT02694809 (https://classic.clinicaltrials.gov/show/NCT02694809)
Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)
NCT ID: NCT04496739 (https://classic.clinicaltrials.gov/show/NCT04496739)
Dedicated Breast CT for Quantitative Breast Density Measurements in Mexican-origin Women in Southern Arizona
NCT ID: NCT04799665 (https://classic.clinicaltrials.gov/show/NCT04799665)
Ruxolitinib for Premalignant Breast Disease
NCT ID: NCT02928978 (https://classic.clinicaltrials.gov/show/NCT02928978)
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study
NCT ID: NCT01247597 (https://classic.clinicaltrials.gov/show/NCT01247597)
PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy 2
NCT ID: NCT04815876 (https://classic.clinicaltrials.gov/show/NCT04815876)
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.